Compare VSH & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSH | ABCL |
|---|---|---|
| Founded | 1962 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 1994 | 2020 |
| Metric | VSH | ABCL |
|---|---|---|
| Price | $28.69 | $12.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $40.50 | $16.82 |
| AVG Volume (30 Days) | 2.6M | ★ 4.8M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 69.57 | 10.91 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $3,069,048,000.00 | $75,128,000.00 |
| Revenue This Year | $20.77 | N/A |
| Revenue Next Year | $16.07 | $7.12 |
| P/E Ratio | $115.46 | ★ N/A |
| Revenue Growth | 4.48 | ★ 160.56 |
| 52 Week Low | $11.77 | $2.75 |
| 52 Week High | $69.47 | $14.98 |
| Indicator | VSH | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 34.81 | 53.05 |
| Support Level | $16.14 | $11.78 |
| Resistance Level | $33.80 | $12.88 |
| Average True Range (ATR) | 1.58 | 0.84 |
| MACD | -0.68 | -0.22 |
| Stochastic Oscillator | 15.20 | 32.95 |
Vishay Intertechnology Inc provides a broad product portfolio of discrete semiconductors and passive electronic components to original equipment manufacturers and distributors. These products are found in industrial, computing, automotive, consumer, telecommunications, power supplies, military, aerospace, and medical markets and serve customer all over the world. Its product segments consist of two general classes: semiconductors and passive components. The company's operating segment includes metal oxide semiconductor field-effect transistors, diodes, optoelectronic components, resistors, inductors, and capacitors. Revenue mainly comes from resistors, which are basic components used in all forms of electronic circuitry to adjust and regulate levels of voltage and current.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.